research Cyproterone Acetate: A Genotoxic Carcinogen?
Cyproterone acetate may cause liver cancer at high doses, but is considered safe at recommended doses for approved uses.
Search
for
Sort by
Research
240-270 / 1000+ results 
research Exogenous Testosterone or Testosterone with Finasteride Increases Bone Mineral Density in Older Men with Low Serum Testosterone
Testosterone therapy increases bone density in older men with low testosterone levels.
research CHRONIC TREATMENT WITH FINASTERIDE DAILY DOES NOT AFFECT SPERMATOGENESIS OR SEMEN PRODUCTION IN YOUNG MEN
Finasteride doesn't harm male fertility or sperm quality, but may slightly reduce ejaculate volume.
research Prostate Cancer Early Detection, Version 2.2015
The guidelines aim to find treatable prostate cancer early while avoiding unnecessary tests and treatments.
research Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts
Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.
research Androgen Receptor Gene Polymorphism and Prostate Zonal Volumes in Australian and Chinese Men
CAG repeat polymorphism and prostate zone volume are not reliable markers of long-term androgen sensitivity.
research Anti-Androgen Effects of Extracts and Compounds fromGanoderma lucidum
Ganoderma lucidum may help treat prostate cancer by blocking male hormones and slowing cancer cell growth.
research Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: A review and pharmacovigilance study
Low testosterone in men is a risk factor for a specific heart rhythm issue, and testosterone treatment may help prevent it.
research The secret identities of TMPRSS2: Fertility factor, virus trafficker, inflammation moderator, prostate protector and tumor suppressor
TMPRSS2 helps viruses enter cells and protects the prostate from inflammation-related cancer.
research The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy
% free PSA and urinary markers help better identify prostate cancer.
research Development of prostate cancer in a patient with primary hypogonadism: intratumoural steroidogenesis in prostate cancer tissues
Prostate cancer can progress even with low testosterone due to internal hormone production in the tumor.
research GYNECOMASTIA AFTER FINASTERIDE THERAPY
Finasteride may cause breast enlargement, low testosterone a risk factor.
research Protective role of agomelatine via modulation of TLR4/NF-κB: NLRP3/IL-1β signaling pathways in testosterone-induced benign prostatic hyperplasia in rats
Agomelatine may help reduce benign prostatic hyperplasia by blocking certain inflammatory pathways.
research Efeitos do uso da finasterida sobre o volume prostático e dosagem sérica do PSA em pacientes jovens
Finasteride reduces prostate size and PSA levels in young patients.
research Prostate cancer and androgenic alopecia: The role of finasteride as a dual agent
Finasteride treats hair loss and reduces prostate cancer risk.
research Finasteride
Finasteride helps hair growth and prostate issues but may cause sexual side effects and increase tumor risk.
research Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases
New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.
research 2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review
Prostate cancer is common, but risk can be reduced by avoiding smoking, unhealthy diet, inactivity, certain medications, and risky jobs.
research Is dehydroepiandrosterone a hormone?
Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.
research Finasteride
Finasteride effectively treats baldness but may cause sexual side effects.
research Urinary Retention in Patients with BPH Treated with Finasteride or Placebo over 4 Years
Finasteride lowers risk of urinary issues and surgery by over 50% in 4 years.
research 9 Role of 5α-reductase in health and disease
5α-reductase is essential for male sexual development and its inhibitors have potential in treating various conditions related to hormone action.
research Testosterone Supplementation for Aging-Associated Sarcopenia
Testosterone supplements can increase muscle mass and strength in older men with low levels, but long-term effects and risks need more research.
research Potential adverse effects of long-term testosterone therapy
Long-term testosterone therapy can cause hormone suppression, affect prostate and heart health, and alter physical characteristics, but does not increase prostate cancer risk and needs more research for full risk assessment.
research Significance of the polyglutamine tract polymorphism in the androgen receptor
The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.
research Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases
Certain drugs that block specific enzymes can help treat prostate diseases.
research A powerful method for pleiotropic analysis under composite null hypothesis identifies novel shared loci between Type 2 Diabetes and Prostate Cancer
New method finds genetic links between Type 2 Diabetes and Prostate Cancer not seen before.
research Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.
research Intermittent Use of Testosterone Inactivating Pharmaceuticals Using Finasteride Prolongs the Time Off Period
Using finasteride with TIP extends time off period for prostate cancer patients.
research Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: a large, cross-sectional, UK epidemiological study
Men with benign prostatic hyperplasia are more likely to have metabolic syndrome than those without it.